BACKGROUND Desmopressin orally disintegrating tablets (ODTs) are widely used to treat arginine vasopressin deficiency (AVP-D). However, limited information is available on the dosage regimen; the dosage for each patient is selected based on their response to the initiation dose. OBJECTIVE To investigate the relationships between clinical characteristics and the daily dose of ODTs and to identify factors that affect ODT dosages. METHODS This retrospective study included 209 adult patients with AVP-D. Patients were administered ODTs sublingually and instructed to restrict eating and drinking for 30 minutes after taking ODTs using a patient leaflet. ODT dose titration was conducted during hospitalization with the close monitoring of urine output, body weight, and serum sodium levels. Multivariable linear regression models were applied to identify clinical factors associated with the daily dose of ODTs at discharge. We also evaluated the dosage at one year in 134 patients who were followed-up in our hospital. RESULTS The median daily dose of ODTs at discharge was 90 µg (IQR 60-120 µg). Multivariable linear regression models identified sex, age, and estimated creatinine clearance (eCCr) as significant factors associated with the daily dose of ODTs, with eCCr having the strongest effect. After excluding patients recovering from AVP-D, 71% of those followed up at our hospital took the same daily dose at one year after discharge. CONCLUSION To achieve the safe and stable treatment of AVP-D, the daily dose of ODT needs to be selected based on a patient's sex, age, and eCCr under appropriate sublingual administration by patient education.

中文翻译：

---

影响精氨酸加压素缺乏症的去氨加压素口腔崩解片每日剂量的临床因素。

背景去氨加压素口腔崩解片(ODT)广泛用于治疗精氨酸加压素缺乏症(AVP-D)。然而，有关剂量方案的信息有限；每个患者的剂量是根据他们对起始剂量的反应来选择的。目的 探讨临床特征与 ODT 每日剂量之间的关系，并确定影响 ODT 剂量的因素。方法 这项回顾性研究纳入了 209 名成年 AVP-D 患者。患者舌下含服 ODT，并使用患者传单指导患者在服用 ODT 后 30 分钟内限制饮食。住院期间进行 ODT 剂量滴定，密切监测尿量、体重和血清钠水平。应用多变量线性回归模型来确定与出院时 ODT 每日剂量相关的临床因素。我们还在我们医院随访的 134 名患者中评估了一年时的剂量。结果 出院时 ODT 的中位每日剂量为 90 µg（IQR 60-120 µg）。多变量线性回归模型将性别、年龄和估计肌酐清除率 (eCCr) 确定为与 ODT 每日剂量相关的重要因素，其中 eCCr 的影响最强。排除 AVP-D 康复患者后，我们医院随访的患者中有 71% 在出院一年后服用了相同的每日剂量。结论 为了实现 AVP-D 的安全、稳定治疗，需要根据患者性别、年龄和 eCCr 选择 ODT 每日剂量，并通过患者教育进行适当的舌下含服给药。